Literature DB >> 2714864

Antimicrobial prophylaxis of experimental endocarditis caused by Staphylococcus epidermidis.

L M Baddour1, M M Hill, A M Felty-Duckworth.   

Abstract

Using two different strains of Staphylococcus epidermidis in a rat model of experimental endocarditis, we examined the prophylactic efficacy of cefamandole (200 mg/kg/dose), cefazolin (200 mg/kg/dose), nafcillin (200 mg/kg/dose), and vancomycin (20 mg/kg/dose). In vitro susceptibility testing demonstrated that both test strains were resistant to methicillin and cefazolin and susceptible to cefamandole and vancomycin. A 10(6) cfu inoculum was used for both strains, an inoculum which produced endocardial infections in greater than 90% of rats. Initial doses of each antibiotic were given 45 min to 1 h prior to bacterial challenge and were followed by six additional doses of each antibiotic administered subcutaneously every 6 h. The efficacy rates of cefamandole (84.0%) and cefazolin (70.8%) were exactly the same for rats infected with either S. epidermidis strain. Similar efficacy rates were seen in rats infected with either strain and treated with vancomycin (94.4% and 86.7%). Unlike the other three drugs, the efficacy of nafcillin was quite different in rats challenged with the two strains (62.5% and 38.5%, p = 0.19). It appears that cefamandole and cefazolin may have considerable prophylactic efficacy against certain infecting strains of methicillin-resistant, coagulase-negative staphylococci when relatively large doses of cephalosporins are administered subcutaneously in this animal model.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2714864     DOI: 10.1007/BF01646884

Source DB:  PubMed          Journal:  Infection        ISSN: 0300-8126            Impact factor:   3.553


  27 in total

1.  Antibiotic susceptibility testing by a standardized single disk method.

Authors:  A W Bauer; W M Kirby; J C Sherris; M Turck
Journal:  Am J Clin Pathol       Date:  1966-04       Impact factor: 2.493

2.  Single-dose rifampin prophylaxis for experimental endocarditis induced by high bacterial inocula of viridans streptococci.

Authors:  R Malinverni; J Bille; M P Glauser
Journal:  J Infect Dis       Date:  1987-07       Impact factor: 5.226

3.  Antimicrobial prophylaxis: a critique of recent trials.

Authors:  J V Hirschmann; T S Inui
Journal:  Rev Infect Dis       Date:  1980 Jan-Feb

4.  Randomized comparison of cefamandole, cefazolin, and cefuroxime prophylaxis in open-heart surgery.

Authors:  T G Slama; S J Sklar; J Misinski; S W Fess
Journal:  Antimicrob Agents Chemother       Date:  1986-05       Impact factor: 5.191

5.  Comparison of cephalothin and cefamandole prophylaxis during insertion of prosthetic heart valves.

Authors:  G L Archer; R E Polk; R J Duma; R Lower
Journal:  Antimicrob Agents Chemother       Date:  1978-06       Impact factor: 5.191

6.  Bacterial adhesion in the pathogenesis of infective endocarditis. Effect of subinhibitory antibiotic concentrations on streptococcal adhesion in vitro and the development of endocarditis in rabbits.

Authors:  W M Scheld; O Zak; K Vosbeck; M A Sande
Journal:  J Clin Invest       Date:  1981-11       Impact factor: 14.808

7.  Vancomycin prophylaxis of experimental Streptococcus sanguis. Inhibition of bacterial adherence rather than bacterial killing.

Authors:  J P Bernard; P Francioli; M P Glauser
Journal:  J Clin Invest       Date:  1981-10       Impact factor: 14.808

8.  Penetration of ceforanide and cefamandole into the right atrial appendage, pericardial fluid, sternum, and intercostal muscle of patients undergoing open heart surgery.

Authors:  L D Mullany; M A French; C H Nightingale; H B Low; L H Ellison; R Quintiliani
Journal:  Antimicrob Agents Chemother       Date:  1982-03       Impact factor: 5.191

9.  Rat model of experimental endocarditis.

Authors:  J Santoro; M E Levison
Journal:  Infect Immun       Date:  1978-03       Impact factor: 3.441

10.  Antibiotic prophylaxis of experimental endocarditis due to methicillin-resistant Staphylococcus epidermidis.

Authors:  G L Archer; G J Vazquez; J L Johnston
Journal:  J Infect Dis       Date:  1980-11       Impact factor: 5.226

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.